Literature DB >> 29146954

Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.

Kalliopi Pitarokoili1, Ralf Gold1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29146954     DOI： 10.1038/nrneurol.2017.161

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  8 in total

1.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Gary Bloomgren; Sandra Richman; Christophe Hotermans; Meena Subramanyam; Susan Goelz; Amy Natarajan; Sophia Lee; Tatiana Plavina; James V Scanlon; Alfred Sandrock; Carmen Bozic
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Robert Hoepner; Eva M Kolb; Stefanie Dahlhaus; Kerstin Hellwig; Ortwin Adams; Ingo Kleiter; Anke Salmen; Ruth Schneider; Carsten Lukas; Andrew Chan; Joseph R Berger; Ralf Gold
Journal:  Mult Scler       Date:  2016-09-06       Impact factor: 6.312

Review 3.  Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification.

Authors:  Nicholas Schwab; Tilman Schneider-Hohendorf; Nico Melzer; Gary Cutter; Heinz Wiendl
Journal:  Neurology       Date:  2017-02-22       Impact factor: 9.910

Review 4.  Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Julian Borchardt; Joseph R Berger
Journal:  Mult Scler Relat Disord       Date:  2016-04-01       Impact factor: 4.339

5.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.

Authors:  Pei-Ran Ho; Harold Koendgen; Nolan Campbell; Bill Haddock; Sandra Richman; Ih Chang
Journal:  Lancet Neurol       Date:  2017-09-29       Impact factor: 44.182

6.  Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Authors:  Tomas Kalincik; J William L Brown; Neil Robertson; Mark Willis; Neil Scolding; Claire M Rice; Alastair Wilkins; Owen Pearson; Tjalf Ziemssen; Michael Hutchinson; Christopher McGuigan; Vilija Jokubaitis; Tim Spelman; Dana Horakova; Eva Havrdova; Maria Trojano; Guillermo Izquierdo; Alessandra Lugaresi; Alexandre Prat; Marc Girard; Pierre Duquette; Pierre Grammond; Raed Alroughani; Eugenio Pucci; Patrizia Sola; Raymond Hupperts; Jeannette Lechner-Scott; Murat Terzi; Vincent Van Pesch; Csilla Rozsa; François Grand'Maison; Cavit Boz; Franco Granella; Mark Slee; Daniele Spitaleri; Javier Olascoaga; Roberto Bergamaschi; Freek Verheul; Steve Vucic; Pamela McCombe; Suzanne Hodgkinson; Jose Luis Sanchez-Menoyo; Radek Ampapa; Magdolna Simo; Tunde Csepany; Cristina Ramo; Edgardo Cristiano; Michael Barnett; Helmut Butzkueven; Alasdair Coles
Journal:  Lancet Neurol       Date:  2017-02-11       Impact factor: 44.182

7.  Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Tatiana Plavina; Meena Subramanyam; Gary Bloomgren; Sandra Richman; Amy Pace; Sophia Lee; Brian Schlain; Denise Campagnolo; Shibeshih Belachew; Barry Ticho
Journal:  Ann Neurol       Date:  2014-10-24       Impact factor: 10.422

Review 8.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

Authors:  C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-10-22       Impact factor: 10.154
  8 in total
  1 in total

Review 1.  Therapeutic Advances in Multiple Sclerosis.

Authors:  Jennifer H Yang; Torge Rempe; Natalie Whitmire; Anastasie Dunn-Pirio; Jennifer S Graves
Journal:  Front Neurol       Date:  2022-06-03       Impact factor: 4.086
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.